lntera 3000 Hepatic Artery Infusion Pump
Intera Oncology · Decision date Feb 26, 2026
What did the FDA approve?
FDA records P890055/S092 as a supplement to PMA P890055, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 26, 2026.
FDA approval order statement
Approval for updates to the labeling and instructions for use.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- General Hospital
- Decision date
- Feb 26, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P890055/S092
- Regulatory pathway
- PMA supplement
- Applicant
- Intera Oncology
- Product code
- LKK
- Decision code
- APPR
- Decision date
- Feb 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pump, infusion, implanted, programmable.
- Applicant
- Intera Oncology
- Product code
- LKK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P890055/S092 received
Application receipt date recorded by FDA.
P890055/S092 · FDA decision
Real-Time Process
P890055/S093 · Related supplement
MEDSTREAM PROGRAMMABLE INFUSION PUMP SYSTEM
Timeline entries are records held by MedtechLedger for P890055. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P890055
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MEDSTREAM PROGRAMMABLE INFUSION PUMP SYSTEMP890055/S093 | Intera Oncology | PMA supplement | Mar 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LKK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 27, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
SynchroMed III Pump Drug Delivery Infusion PumpP860004/S461 | Medtronic, Inc. | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Intera Oncology
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 180 Wells Ave., Suite 300a, Newton, MA, 02459
Sources and methodology
- Original FDA record: P890055/S092
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

